Summit PLC, developer of experimental Duchenne muscular dystrophy drug SMT C1100, announced additional encouraging findings regarding this drug’s apparent effects on DMD-affected muscles. In an October 8, 2014 press release, Summit reported:
- C1100 was safe and well tolerated at all doses tested and a statistically significant reduction observed in plasma levels of three enzymes associated with muscle damage. Variability from patient to patient in the blood plasma levels of SMT C1100 was also observed and will be explored in future patient clinical studies.
- Positive preclinical data on second generation utrophin modulators showed their enhanced bioavailability compared to SMT C1100 and their ability to increase expression of utrophin, improve the disease pathology, reduce muscle regeneration and protect muscle function
All data are being presented at the 19th International World Muscle Society Congress (‘WMS’) being held in Berlin, Germany from October 7-11, 2014. For more information read:DMD: Encouraging Results for SMT C1100.
Full Article: http://quest.mda.org/news/update-dmd-encouraging-results-smt-c1100